CSBio CSBio

X
[{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Menarini"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Nerviano Medical Sciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types.

            Lead Product(s): NMS-293

            Therapeutic Area: Oncology Product Name: NMS-03305293

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Merck & Co

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Results of the phase 1b dose escalation study of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer will be presented at the 2020 Virtual Annual Congress of the European Society for Medical Oncology.

            Lead Product(s): MEN1611,Trastuzumab,Fulvestrant

            Therapeutic Area: Oncology Product Name: MEN1611

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY